Invivyd, a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of...
Read Story
|
Kashiv BioSciences, a fully integrated biopharmaceutical company, entered into a senior secured credit agreement with GoldenTree Asset Management as the sole lender. The $150 million credit facility supports Kashiv BioSciences in advancing its...
Read Story
|
CalciMedica, a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, entered into a credit facility...
Read Story
|
Inhibrx Biosciences, a biopharmaceutical company with two programs in ongoing clinical trials, entered into a loan and security agreement with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders")...
Read Story
January 14, 2025, 08:15 AM
|
Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, has obtained a $200 million non-dilutive term loan...
Read Story
November 11, 2024, 08:08 AM
|
SSG Capital Advisors served as the investment banker to Eiger BioPharmaceuticals, Inc. in the sale of Lonafarnib and Lambda, and associated clinical assets to Eiger InnoTherapeutics, Inc. The sale was effectuated through a Chapter 11 Section 363...
Read Story
September 13, 2024, 07:47 AM
|
SSG Capital Advisors served as the investment banker to Eiger BioPharmaceuticals, Inc. in the sale of Avexitide and its related clinical assets to Amylyx Pharmaceuticals, Inc. The sale was effectuated through a Chapter 11 Section 363 process in the U...
Read Story
|
SSG Capital Advisors served as the investment banker to Eiger BioPharmaceuticals, Inc. in the sale of substantially all of its assets related to the FDA-approved drug Zokinvy®, to Sentynl Therapeutics, Inc. The sale was effectuated through a Chapter...
Read Story
|
Xeris Biopharma Holdings entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP to provide Xeris $200.0 million of capital at close and the ability to draw down...
Read Story
|
iBio, an AI-driven innovator of precision antibody immunotherapies, announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank, have entered into an amendment to the Credit Agreement dated November 1, 2021...
Read Story
December 27, 2023, 07:00 AM
|
ADMA Biologics, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced the Company has executed a definitive credit agreement with Ares Management credit...
Read Story
December 19, 2023, 07:49 AM
|
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), entered into a senior secured loan and...
Read Story
November 13, 2023, 07:50 AM
|
Sorrento Therapeutics, a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced that the U.S. Bankruptcy Court for the Southern District of Texas granted...
Read Story
|
FibroGen announced a royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth. NovaQuest is a strategic...
Read Story
November 08, 2022, 07:45 AM
|
Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.The term loan facility provides for up to $125 million of term...
Read Story
September 01, 2022, 07:50 AM
|
Hansa Biopharma AB, (Hansa), a pioneer in enzyme technology for rare immunological conditions, has entered into an agreement with U.S.-based NovaQuest Capital Management, securing $70 million in non-dilutive financing."This transaction, which extends...
Read Story
|
Savara, a clinical stage biopharmaceutical company focused on rare respiratory diseases, entered into a term loan agreement of $26.5 million with Silicon Valley Bank to replace its existing credit facility with the bank. The new facility represents a...
Read Story
|
BioXcel Therapeutics, a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced strategic financing agreements with funds managed by...
Read Story
|
Xeris Biopharma Holdings entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management to provide Xeris with up to a total of $150 million of capital.Under the terms of the debt facility, Xeris drew down $100...
Read Story
|
Ardelyx, a biopharmaceutical company, announced it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners."We are pleased to enter into this agreement with SLR for non-dilutive capital ahead of an...
Read Story
February 25, 2022, 08:03 AM
|
Amryt, a global, commercial-stage biopharmaceutical company secured $125 million of senior credit facilities from funds managed by the Credit Group of Ares Management Corporation. Amryt will use a portion of the proceeds to refinance its previous...
Read Story
February 23, 2022, 07:18 AM
|
Corium, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, closed on a $235 million term loan agreement with Hercules Capital. Corium will receive an initial...
Read Story
September 29, 2021, 07:32 AM
|